Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27042192 | 0.84 | CYP3A4 (0.50) | — | |
| SCHEMBL10906346 | 0.83 | CYP3A4 (0.48) | — | |
| SCHEMBL32660821 | 0.82 | LMNA (0.44) | CETPPPARGPPARA | |
| SCHEMBL32660809 | 0.81 | CYP3A4 (0.47) | — | |
| SCHEMBL9238036 | 0.81 | LPAR3 (0.56) | CETP | |
| SCHEMBL9236687 | 0.80 | GGPS1 (0.49) | CETP | |
| SCHEMBL4135807 | 0.80 | CETP (0.59) | HPGDCETPSMN1; SMN2PPARGPPARA | |
| SCHEMBL28676569 | 0.80 | LPAR3 (0.47) | — | |
| SCHEMBL1100487 | 0.80 | ALDH1A1 (0.52) | CETP | |
| SCHEMBL28022001 | 0.80 | LTA4H (0.50) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | JAL THERAPEUTICS LLC (US) | 2026-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | ACHE, BCHE, MUSK | HPGD 3786/4885CETP 75/4885SMN1; SMN2 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.